Monday, January 18, 2021
Home Clinical Research What is Phase-III Clinical Trial?

What is Phase-III Clinical Trial?

“Phase III trials are conducted to confirm and expand on the safety and effectiveness results from Phase I and II trials, to compare the drug to the standard therapies for the disease or condition being studied, and to evaluate the overall risks and benefits of the drug.

Phase III studies are commonly randomized multicenter controlled trials on large patient populations (300–3,000 or more depending on the disease/medical condition studied) and are meant to be the definitive measure of how successful the medication is relative to the existing ‘gold standard’ treatment.

- Advertisement -

Phase III aim is to determine how the new medication performs for the same condition relative to existing drugs.

Before continuing with the experiment, researchers need to show that the drug is at least as safe and successful as the treatment options that exist.

Because of their size and relatively long duration, Phase III trials are the most expensive, time-consuming and difficult trials to design and run, especially in therapies for chronic medical conditions.

Once a drug has proved acceptable after Phase III trials, the trial results are generally combined into a large document containing a comprehensive description of the methods and results of the human and animal studies, manufacturing procedures, formulation details, and shelf life.

This collection of information makes up the “regulatory submission” that is provided for review to the suitable regulatory authoritiesin different countries.

Most drugs undergoing Phase III clinical trials can be marketed under FDA norms with the proper recommendations and guidelines through a New Drug Application (NDA) containing all the manufacturing, preclinical, and clinical data.

In case of any side effects being reported anywhere, the drugs need to be recalled without any delay from the market.”


Please enter your comment!
Please enter your name here

four + fifteen =

Most Popular

GSK presents positive efficacy data of dostarlimab at ASCO Gastrointestinal Cancers Symposium

January 16, 2021: "GlaxoSmithKline (GSK) plc announced updated data from GARNET cohort F evaluating dostarlimab in mismatch repair-deficient (dMMR) non-endometrial advanced solid...

Bharat Biotech signs agreement with Precisa Medicamentos for supply of ‘COVAXIN™’ to Brazil

January 12, 2020: "Bharat Biotech announced that it has signed an agreement with Precisa Medicamentos for the supplies of COVAXIN™ to Brazil.

What Is a Blockbuster Drug?

What Is a Blockbuster Drug? "Blockbuster drugs are those that generate at least $1 billion of revenue per...

Boehringer Ingelheim and Enara Bio join forces to discover Cancer Immunotherapies

January 12th, 2021: Boehringer Ingelheim and Enara Bio announced that they have entered into a strategic collaboration and licensing agreement to research...